MA
IOVA icon

MYDA Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

MYDA Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,000
Closed -$332K – 148
2019
Q4 		$332K Buy
+12,000
New +$273K 0.14% 86

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

MYDA Advisors's IOVA Position: Q2 2020 in Review

MYDA Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 8,400 shares — an estimated $251K sold.

MYDA Advisors first reported a position in IOVA in Q4 2019 and held it in 2 quarters. The position peaked at $747K in Q4 2019. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • MYDA Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • MYDA Advisors sold 8,400 Iovance Biotherapeutics shares in Q2 2020, an estimated $251K.
  • MYDA Advisors first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 2 quarters.
  • MYDA Advisors's Iovance Biotherapeutics position peaked at $747K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on MYDA Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.